Transmucosal dosage forms of remdesivir
US11020349B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 14, 2020 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | Jul 14, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.